Zalypsis has in vitro activity in acute myeloid blasts and leukemic progenitor cells through the induction of a DNA damage response

Haematologica

Volumn 96, Issue 5, 2011, Pages 687-695

  Calado, Enrique ^a,b   Paíno, Teresa ^a   Maiso, Patriciasa ^a   Ocio, Enrique M ^a,b   Chen, Xi ^a   Álvarez Fernández, Stela ^a   Gutiérrez, Norma C ^a,b   Martín Sánchez, Jesús ^a,b   Flores Montero, Juan ^a   Segundo, Laura San ^a   Garayoa, Mercedes ^a   Fernández Lázaro, Diego ^a   Vidriales, Maria Belen ^b   Galmarini, Carlos M ^c   Avilés, Pablo ^c   Cuevas, Carmen ^c   Pandiella, Atanasio ^a   San Miguel, Jesús F ^a,b  

^a CSIC   (Spain)

^b HOSPITAL UNIVERSITARIO DE SALAMANCA   (Spain)

^c PHARMAMAR S A   (Spain)

Author keywords

Acute myeloid leukemia; Antileukemic activity; DNA damage response; Zalypsis

Indexed keywords

ALKALOID DERIVATIVE; ANTILEUKEMIC AGENT; CD34 ANTIGEN; CD38 ANTIGEN; CHECKPOINT KINASE 1; CHECKPOINT KINASE 2; CYTARABINE; DAUNORUBICIN; FLUDARABINE; HISTONE H2AX; UNCLASSIFIED DRUG; ZALYPSIS;

ACUTE GRANULOCYTIC LEUKEMIA; ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTICLE; BLAST CELL; CONTROLLED STUDY; DOUBLE STRANDED DNA BREAK; DRUG POTENCY; DRUG POTENTIATION; FANCONI ANEMIA GENE; FLOW CYTOMETRY; GENE; GENE CONTROL; GENE EXPRESSION PROFILING; HUMAN; HUMAN CELL; LEUKEMIA CELL; RAD51 GENE; RAD54 GENE; TUMOR SUPPRESSOR GENE; WESTERN BLOTTING;

ANTINEOPLASTIC AGENTS; APOPTOSIS; BLOTTING, WESTERN; BRCA1 PROTEIN; CASPASES; CELL LINE, TUMOR; CELL PROLIFERATION; CELL SURVIVAL; DNA BREAKS, DOUBLE-STRANDED; DNA DAMAGE; DOSE-RESPONSE RELATIONSHIP, DRUG; FLOW CYTOMETRY; GENE EXPRESSION PROFILING; GENE EXPRESSION REGULATION, LEUKEMIC; HL-60 CELLS; HUMANS; LEUKEMIA, MYELOID, ACUTE; MITOCHONDRIA; OLIGONUCLEOTIDE ARRAY SEQUENCE ANALYSIS; RAD51 RECOMBINASE; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; STEM CELLS; TETRAHYDROISOQUINOLINES; TUMOR CELLS, CULTURED;

EID: 79955733795     PISSN: 03906078     EISSN: 15928721     Source Type: Journal    
DOI: 10.3324/haematol.2010.036400     Document Type: Article

References (40)

1. Estey E. New drugs in acute myeloid leukemia. Semin Oncol. 2008;35 (4):439-48.
2. Jabbour EJ, Estey EJ, Kantarjian HM. Adult acute myeloid leukemia. Mayo Clin Proc. 2006;81(2):247-60.
3. Lowenberg B. Acute myeloid leukemia: the challenge of capturing disease variety. Hematology / The Education Program of the American Society of Hematology American Society of Hematology. 2008;1-11.
4. Tallman MS, Gilliland DG, Rowe JM. Drug therapy for acute myeloid leukemia. Blood. 2005;106(4):1154-63.
5. Warner JK, Wang JC, Hope KJ, Jin L, Dick JE. Concepts of human leukemic development. Oncogene. 2004;23(43):7164-77.
6. Misaghian N, Ligresti G, Steelman LS, Bertrand FE, Basecke J, Libra M, et al. Targeting the leukemic stem cell: the Holy Grail of leukemia therapy. Leukemia. 2009;23(1):25-42.
7. Byrd JC, Mrozek K, Dodge RK, Carroll AJ, Edwards CG, Arthur DC, et al. Pretreatment cytogenetic abnormalities are predictive of induction success, cumulative incidence of relapse, and overall survival in adult patients with de novo acute myeloid leukemia: results from Cancer and Leukemia Group B (CALGB 8461). Blood. 2002;100(13):4325-36.
8. Lowenberg B, Griffin JD, Tallman MS. Acute myeloid leukemia and acute promyelocytic leukemia. Hematology / The Education Program of the American Society of Hematology American Society of Hematology. 2003:82-101.
9. Breems DA, Van Putten WL, Huijgens PC, Ossenkoppele GJ, Verhoef GE, Verdonck LF, et al. Prognostic index for adult patients with acute myeloid leukemia in first relapse. J Clin Oncol. 2005;23(9):1969-78.
10. Haferlach C, Dicker F, Herholz H, Schnittger S, Kern W, Haferlach T. Mutations of the TP53 gene in acute myeloid leukemia are strongly associated with a complex aberrant karyotype. Leukemia. 2008;22(8):1539-41.
11. Fenaux P, Jonveaux P, Quiquandon I, Lai JL, Pignon JM, Loucheux-Lefebvre MH, et al. P53 gene mutations in acute myeloid leukemia with 17p monosomy. Blood. 1991;78(7):1652-7.
12. Fenaux P, Preudhomme C, Quiquandon I, Jonveaux P, Lai JL, Vanrumbeke M, et al. Mutations of the P53 gene in acute myeloid leukaemia. Br J Haematol. 1992;80(2):178-83.
13. Merlat A, Lai JL, Sterkers Y, Demory JL, Bauters F, Preudhomme C, et al. Therapyrelated myelodysplastic syndrome and acute myeloid leukemia with 17p deletion. A report on 25 cases. Leukemia. 1999; 13(2):250-7.
14. Stirewalt DL, Kopecky KJ, Meshinchi S, Appelbaum FR, Slovak ML, Willman CL, et al. FLT3, RAS, and TP53 mutations in elderly patients with acute myeloid leukemia. Blood. 2001;97(11):3589-95.
15. McCubrey JA, Abrams SL, Ligresti G, Misaghian N, Wong EW, Steelman LS, et al. Involvement of p53 and Raf/MEK/ERK pathways in hematopoietic drug resistance. Leukemia. 2008;22(11):2080-90.
16. Molinski TF, Dalisay DS, Lievens SL, Saludes JP. Drug development from marine natural products. Nat Rev Drug Discov. 2009;8(1):69-85.
17. Carter NJ, Keam SJ. Trabectedin: a review of its use in the management of soft tissue sarcoma and ovarian cancer. Drugs. 2007;67(15):2257-76.
18. Ocio EM, Maiso P, Chen X, Garayoa M, Alvarez-Fernandez S, San-Segundo L, et al. Zalypsis: A novel marine-derived compound with potent antimyeloma activity that reveals high sensitivity of malignant plasma cells to DNA double strand breaks. Blood. 2008;113(16):3781-91.
19. Leal JF, Garcia-Hernandez V, Moneo V, Domingo A, Bueren-Calabuig JA, Negri A, et al. Molecular pharmacology and antitumor activity of zalypsis in several human cancer cell lines. Biochem Pharmacol. 2009;78(2):162-70.
20. Colado E, Alvarez-Fernandez S, Maiso P, Martin-Sanchez J, Vidriales MB, Garayoa M, et al. The effect of the proteasome inhibitor bortezomib on acute myeloid leukemia cells and drug resistance associated with the CD34+ immature phenotype. Haematologica. 2008;93(1):57-66.
21. Maiso P, Carvajal-Vergara X, Ocio EM, Lopez-Perez R, Mateo G, Gutierrez N, et al. The histone deacetylase inhibitor LBH589 is a potent antimyeloma agent that overcomes drug resistance. Cancer Res. 2006;66(11):5781-9.
22. Maiso P, Colado E, Ocio EM, Garayoa M, Martin-Sanchez J, Atadja P, et al. The synergy of panobinostat plus doxorubicin in acute myeloid leukemia suggests a role for HDAC inhibitors in the control of DNA repair. Leukemia. 2009;23(12):2265-74.
23. Orfao A, Ortuno F, de Santiago M, Lopez A, San Miguel J. Immunophenotyping of acute leukemias and myelodysplastic syndromes. Cytometry A. 2004;58(1):62-71.
24. Koopman G, Reutelingsperger CP, Kuijten GA, Keehnen RM, Pals ST, van Oers MH. Annexin V for flow cytometric detection of phosphatidylserine expression on B cells undergoing apoptosis. Blood. 1994;84(5):1415-20.
25. Steensma DP, Timm M, Witzig TE. Flow cytometric methods for detection and quantification of apoptosis. Methods Mol Med. 2003;85:323-32.
26. Ozgen U, Savasan S, Buck S, Ravindranath Y. Comparison of DiOC(6)(3) uptake and annexin V labeling for quantification of apoptosis in leukemia cells and non-malignant T lymphocytes from children. Cytometry. 2000;42(1):74-8.
27. Guzman ML, Swiderski CF, Howard DS, Grimes B, Rossi RM, Szilvassy SJ, et al. Preferential induction of apoptosis for primary human leukemic stem cells. PNAS. 2002;99(25):16220-5.
28. Testa U, Riccioni R. Deregulation of apoptosis in acute myeloid leukemia. Haematologica. 2007;92(1):81-94.
29. Zamzami N, Marchetti P, Castedo M, Zanin C, Vayssiere JL, Petit PX, et al. Reduction in mitochondrial potential constitutes an early irreversible step of programmed lymphocyte death in vivo. J Exp Med. 1995;181(5):1661-72.
30. Vandenabeele P, Vanden Berghe T, Festjens N. Caspase inhibitors promote alternative cell death pathways. Sci STKE. 2006; 2006(358):pe44.
31. Williams GH, Stoeber K. Cell cycle markers in clinical oncology. Curr Opin Cell Biol. 2007;19(6):672-9.
32. Williams RS, Williams JS, Tainer JA. Mre11- Rad50-Nbs1 is a keystone complex connecting DNA repair machinery, doublestrand break signaling, and the chromatin template. Biochem Cell Biol. 2007;85(4): 509-20.
33. Rupnik A, Lowndes NF, Grenon M. MRN and the race to the break. Chromosoma. 2009;119(2): 115-135.
34. Shrivastav M, De Haro LP, Nickoloff JA. Regulation of DNA double-strand break repair pathway choice. Cell Res. 2008;18 (1):134-47.
35. Kinner A, Wu W, Staudt C, Iliakis G. Gamma-H2AX in recognition and signaling of DNA double-strand breaks in the context of chromatin. Nucleic Acids Res. 2008;36(17):5678-94.
36. Rizzo MG, Zepparoni A, Cristofanelli B, Scardigli R, Crescenzi M, Blandino G, et al. Wt-p53 action in human leukaemia cell lines corresponding to different stages of differentiation. Br J Cancer. 1998;77(9): 1429-38.
37. Suela J, Alvarez S, Cifuentes F, Largo C, Ferreira BI, Blesa D, et al. DNA profiling analysis of 100 consecutive de novo acute myeloid leukemia cases reveals patterns of genomic instability that affect all cytogenetic risk groups. Leukemia. 2007;21(6): 1224-31.
38. Sallmyr A, Fan J, Rassool FV. Genomic instability in myeloid malignancies: increased reactive oxygen species (ROS), DNA double strand breaks (DSBs) and error-prone repair. Cancer Lett. 2008;270 (1):1-9.
39. Rassool FV, Gaymes TJ, Omidvar N, Brady N, Beurlet S, Pla M, et al. Reactive oxygen species, DNA damage, and error-prone repair: a model for genomic instability with progression in myeloid leukemia? Cancer Res. 2007;67(18):8762-71.
40. Martin SA, Lord CJ, Ashworth A. DNA repair deficiency as a therapeutic target in cancer. Curr Opin Genet Dev. 2008;18(1): 80-6.